| Basal insulin requirements on continuous subcutaneous insulin infusion during the first 12 months after diagnosis of type 1 diabetes mellitus. | |
| | |
MedLine Citation:
|
PMID: 20513327 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
INTRODUCTION: While the endogenous first-phase insulin response has disappeared by the time of diagnosis of type 1 diabetes mellitus (T1DM), anecdotal evidence suggests that these patients can continue to have a second-phase insulin response during the first 12 months after diagnosis. We hypothesized that patients who are started on continuous subcutaneous insulin infusion (CSII) at the time of diagnosis of T1DM would have a lower basal insulin requirement than the 40-60% usually expected. METHODS: We analyzed 38 patients with T1DM, age 9.9 +/- 6.4 years, 71% male, who were started on CSII within the first month of diagnosis. RESULTS: Average basal insulin requirements were 47-49% of total daily dose during the first 12 months after diagnosis and decreased from 0.30 U/kg/day at diagnosis to 0.20 U/kg/day by 12 months. Baseline percentage of basal insulin was significantly correlated with hemoglobin A1c at baseline and at six months. The percentage of basal insulin requirement at 12 months after diagnosis was significantly correlated with baseline body mass index (BMI) and current BMI. No other correlations between percentage of basal insulin requirements and any other factors were seen. CONCLUSION: Our data suggest that, even though some endogenous insulin production remains during the first year after diagnosis of T1DM, the distribution of basal versus total daily insulin requirements remains the same as in the general population of people with diabetes. There may be benefits to starting patients on a higher basal rate at time of diagnosis for overall glycemic control during the first six months. Further research is needed to optimize starting insulin doses to maximize their potential in preserving beta-cell function. |
| | |
Authors:
|
Neesha Ramchandani; Mary Kristine Ellis; Shobhit Jain; Sonal Bhandari; Henry Anhalt; Noel K Maclaren; Svetlana Ten |
Related Documents
:
|
9204617 - Usefulness of cryohemolysis test in the diagnosis of hereditary spherocytosis. 3095407 - Necrotizing fasciitis precipitating diabetic ketoacidotic coma. 194537 - Necrolytic migratory erythema. distinctive dermatosis of the glucagonoma syndrome. 3021697 - Insulinoma in a ferret. 21855157 - Changes in the arginine methylation of organ proteins during the development of diabete... 15013477 - Long-term metabolic consequences of being born small for gestational age. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-05-01 |
Journal Detail:
|
Title: Journal of diabetes science and technology Volume: 4 ISSN: 1932-2968 ISO Abbreviation: J Diabetes Sci Technol Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-06-01 Completed Date: 2010-11-16 Revised Date: 2011-07-28 |
Medline Journal Info:
|
Nlm Unique ID: 101306166 Medline TA: J Diabetes Sci Technol Country: United States |
Other Details:
|
Languages: eng Pagination: 610-4 Citation Subset: IM |
Copyright Information:
|
(c) 2010 Diabetes Technology Society. |
Affiliation:
|
Department of Pediatric Endocrinology, Maimonides Medical Center, Brooklyn, New York 11219 , USA. NRamchandani@maimonidesmed.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Area Under Curve Blood Glucose / analysis, drug effects Body Mass Index Child Child, Preschool Diabetes Mellitus, Type 1 / blood, drug therapy* Female Hemoglobin A, Glycosylated / analysis Humans Hypoglycemic Agents / administration & dosage* Infant Infusions, Subcutaneous Insulin / administration & dosage, analogs & derivatives* Insulin Infusion Systems* Male Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Blood Glucose; 0/Hemoglobin A, Glycosylated; 0/Hypoglycemic Agents; 0/basal insulin; 0/hemoglobin A1c protein, human; 11061-68-0/Insulin |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Comparison pharmacokinetics of two concentrations (0.7% and 1.0%) of Nasulin, an ultra-rapid-acting ...
Next Document: Extended prandial glycemic profiles of foods as assessed using continuous glucose monitoring enhance...